411 related articles for article (PubMed ID: 20479694)
21. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
[TBL] [Abstract][Full Text] [Related]
23. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P
Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Kim YS; Park SH; Kyung SY; Sym SJ; Lee SP; Park JW; Jung SH; Park J; Cho EK; Lee JH; Shin DB
Med Oncol; 2011 Mar; 28(1):342-50. PubMed ID: 20198458
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
31. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
[TBL] [Abstract][Full Text] [Related]
32. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
[TBL] [Abstract][Full Text] [Related]
33. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
34. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.
Hong YS; Lee HR; Park S; Lee SC; Hwang IG; Park BB; Lee J; Ahn JS; Ahn MJ; Lim HY; Park K
Br J Cancer; 2006 Dec; 95(12):1648-52. PubMed ID: 17133266
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
36. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
